Literature DB >> 11044103

Development of multigene and regulated lentivirus vectors.

J Reiser1, Z Lai, X Y Zhang, R O Brady.   

Abstract

Previously we described safe and efficient three-component human immunodeficiency virus type 1 (HIV-1)-based gene transfer systems for delivery of genes into nondividing cells (H. Mochizuki, J. P. Schwartz, K. Tanaka, R. O. Brady, and J. Reiser, J. Virol. 72:8873-8883, 1998). To apply such vectors in anti-HIV gene therapy strategies and to express multiple proteins in single target cells, we have engineered HIV-1 vectors for the concurrent expression of multiple transgenes. Single-gene vectors, bicistronic vectors, and multigene vectors expressing up to three exogenous genes under the control of two or three different transcriptional units, placed within the viral gag-pol coding region and/or the viral nef and env genes, were designed. The genes encoding the enhanced version of green fluorescent protein (EGFP), mouse heat-stable antigen (HSA), and bacterial neomycin phosphotransferase were used as models whose expression was detected by fluorescence-activated cell sorting, fluorescence microscopy, and G418 selection. Coexpression of these reporter genes in contact-inhibited primary human skin fibroblasts (HSFs) persisted for at least 6 weeks in culture. Coexpression of the HSA and EGFP reporter genes was also achieved following cotransduction of target cells using two separate lentivirus vectors encoding HSA and EGFP, respectively. For the regulated expression of transgenes, tetracycline (Tet)-regulatable lentivirus vectors encoding the reverse Tet transactivator (rtTA) and EGFP controlled by a Tet-responsive element (TRE) were constructed. A binary HIV-1-based vector system consisting of a lentivirus encoding rtTA and a second lentivirus harboring a TRE driving the EGFP reporter gene was also designed. Doxycycline-modulated expression of the EGFP transgene was confirmed in transduced primary HSFs. These versatile vectors can potentially be used in a wide range of gene therapy applications.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044103      PMCID: PMC110933          DOI: 10.1128/jvi.74.22.10589-10599.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  HIV-1 reverse transcription. A termination step at the center of the genome.

Authors:  P Charneau; G Mirambeau; P Roux; S Paulous; H Buc; F Clavel
Journal:  J Mol Biol       Date:  1994-09-02       Impact factor: 5.469

2.  Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors.

Authors:  T Kafri; U Blömer; D A Peterson; F H Gage; I M Verma
Journal:  Nat Genet       Date:  1997-11       Impact factor: 38.330

3.  Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1.

Authors:  V N Kim; K Mitrophanous; S M Kingsman; A J Kingsman
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

4.  Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo.

Authors:  R Zufferey; D Nagy; R J Mandel; L Naldini; D Trono
Journal:  Nat Biotechnol       Date:  1997-09       Impact factor: 54.908

5.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.

Authors:  J He; S Choe; R Walker; P Di Marzio; D O Morgan; N R Landau
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette.

Authors:  A Hofmann; G P Nolan; H M Blau
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

7.  High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G.

Authors:  R K Akkina; R M Walton; M L Chen; Q X Li; V Planelles; I S Chen
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells.

Authors:  W Paulus; I Baur; F M Boyce; X O Breakefield; S A Reeves
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

Review 9.  Gene therapy for human immunodeficiency virus infection: genetic antiviral strategies and targets for intervention.

Authors:  B Dropulić; K T Jeang
Journal:  Hum Gene Ther       Date:  1994-08       Impact factor: 5.695

10.  In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Authors:  L Naldini; U Blömer; P Gallay; D Ory; R Mulligan; F H Gage; I M Verma; D Trono
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

View more
  31 in total

1.  Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors.

Authors:  Z Lai; I Han; G Zirzow; R O Brady; J Reiser
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

2.  Design of an HIV-1 lentiviral-based gene-trap vector to detect developmentally regulated genes in mammalian cells.

Authors:  Zhennan Lai; Ina Han; Misun Park; Roscoe O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

3.  Biochemical and functional analysis of a 9-nt RNA sequence that affects translation efficiency in eukaryotic cells.

Authors:  Stephen A Chappell; Gerald M Edelman; Vincent P Mauro
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

Review 4.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

Review 5.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

Review 6.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

7.  Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors.

Authors:  Robert H Kutner; Xian-Yang Zhang; Jakob Reiser
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

Review 8.  Methods for gene transfer to the central nervous system.

Authors:  Boris Kantor; Rachel M Bailey; Keon Wimberly; Sahana N Kalburgi; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

9.  Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction.

Authors:  Barbara Mitta; Markus Rimann; Markus U Ehrengruber; Martin Ehrbar; Valentin Djonov; Jens Kelm; Martin Fussenegger
Journal:  Nucleic Acids Res       Date:  2002-11-01       Impact factor: 16.971

10.  Design and in vivo characterization of self-inactivating human and non-human lentiviral expression vectors engineered for streptogramin-adjustable transgene expression.

Authors:  Barbara Mitta; Cornelia C Weber; Markus Rimann; Martin Fussenegger
Journal:  Nucleic Acids Res       Date:  2004-07-16       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.